ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1107

An Illness By Any Other Name: The Effect of Changing the Disease Label of Gout on the Perceptions of the Illness and Its Management

Keith Petrie1, Kate MacKrill1, Christina Derksen2 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2University of Marburg, Marburg, Germany

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Gout is a chronic disease caused by deposition of monosodium urate crystals.  Although diet is a risk factor, many other factors also contribute to development of gout, including age, male sex, kidney disease and genetic variants.  Historical and contemporary narratives frequently depict gout as an acute condition caused by dietary overindulgence.  These perceptions of illness may have a negative impact on healthcare-seeking and management strategies. The aim of this study was to examine the effect of changing the disease label of gout on the perceptions of the illness and its management.   

Methods: Supermarket shopper participants were recruited into this study (n=189).  Participants were advised that the aim of the study was to examine the perceptions of different types of arthritis. Participants were randomised to read an identical description of an illness labelled as either gout or urate crystal arthritis (UCA), and complete a questionnaire examining their perception of the illness, likely causal factors, and the usefulness of various management strategies.  The label urate crystal arthritis was selected to represent the core pathophysiological elements of disease, including urate as the causative biochemical substrate, crystal deposition, and joint inflammation.   Differences between the two illness labels were tested using independent sample t-tests.

 

Results: The gout-labelled illness was attributed more to patient behaviour (p = 0.030) through poor diet (p = 0.013) and overconsumption of alcohol (p = 0.039), while the UCA- labelled illness was attributed more to aging (p = 0.006).  There were no differences in beliefs about other causal factors.  The gout-labelled illness was viewed as under more personal control (p = 0.001) and as more socially embarrassing (p < 0.001), whereas the UCA- labelled illness was viewed as having a more chronic timeline (p = 0.044) and as a more serious condition (p = 0.037).  Changing to a healthier diet was perceived as more helpful for the gout-labelled illness (p = 0.014).  In contrast, taking long-term medications for the condition was viewed as more helpful for the UCA-labelled illness (p = 0.041).  There was no significant difference between the illness labels in perceptions that reducing stress, adopting regular exercise, losing weight or using alternative medicine would be helpful for managing the illness (p for all >0.08).

Conclusion: The negative cultural stereotypes surrounding the disease label gout may be a barrier to effective treatment.  Changing the name of the illness from gout to a pathophysiological illness label such urate crystal arthritis may have a positive benefits for patient understanding of the condition and the adoption of effective management strategies. 

 


Disclosure: K. Petrie, None; K. MacKrill, None; C. Derksen, None; N. Dalbeth, Takeda, AstraZeneca, Abbvie, 9.

To cite this abstract in AMA style:

Petrie K, MacKrill K, Derksen C, Dalbeth N. An Illness By Any Other Name: The Effect of Changing the Disease Label of Gout on the Perceptions of the Illness and Its Management [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/an-illness-by-any-other-name-the-effect-of-changing-the-disease-label-of-gout-on-the-perceptions-of-the-illness-and-its-management/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-illness-by-any-other-name-the-effect-of-changing-the-disease-label-of-gout-on-the-perceptions-of-the-illness-and-its-management/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology